Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2024, for GlycoMimetics, Inc. (trading symbol: GLYC). The company is a biotechnology firm that previously developed glycomimetics, including the lead candidate uproleselan for acute myeloid leukemia. Following negative Phase 3 trial results and FDA feedback indicating the need for additional trials, the company ceased clinical activities in July 2024, reduced its workforce by approximately 80%, and initiated a strategic review. On October 28, 2024, the company entered into a merger agreement with Crescent Biopharma, Inc., under which it will become a wholly-owned subsidiary and operate as Crescent Biopharma, Inc. The merger is expected to close in Q2 2025.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | 9 Months 2024 | 9 Months 2023 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(9.82) million | $(9.20) million | $(30.66) million | $(27.82) million |
| Net Loss Per Share | $(0.15) | $(0.14) | $(0.48) | $(0.44) |
| Cash and Cash Equivalents (End of Period) | $14.39 million | $49.41 million | $14.39 million | $49.41 million |
| Operating Cash Flow (9 Months) | $(27.40) million | $(27.26) million | $(27.40) million | $(27.26) million |
| Total Assets | $15.70 million | $45.32 million | $15.70 million | $45.32 million |
| Total Liabilities | $4.32 million | $6.90 million | $4.32 million | $6.90 million |
Material Changes vs. Prior Period
- Restructuring Charges: The company incurred $5.51 million in restructuring and asset impairment charges in Q3 2024, compared to zero in Q3 2023. This included $5.0 million in severance costs following an 80% workforce reduction and $0.4 million in lease and asset impairments.
- Expense Reduction: Research and development expenses decreased by 68% in Q3 2024 ($1.72 million) compared to Q3 2023 ($5.29 million) due to the cessation of clinical trials. General and administrative expenses decreased by 11% in Q3 2024.
- Cash Position: Cash and cash equivalents declined significantly from $41.79 million at year-end 2023 to $14.39 million at September 30, 2024, driven by operating losses and the lack of new equity financing in the current period.
- Asset Sale: The company recorded a $1.22 million gain on the sale of rights to the asset "rivipansel" in Q3 2024.
Outlook, Risks, and Contingencies
- Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern for one year from the filing date. Current cash resources are expected to fund operations only until the closing of the proposed merger and concurrent private placement.
- Merger and Financing: The company plans to merge with Crescent Biopharma, Inc., with a concurrent private placement of approximately $200 million. Upon closing, pre-merger GlycoMimetics stockholders are expected to own approximately 3.1% of the combined company.
- Nasdaq Compliance: The company received notice from Nasdaq regarding non-compliance with the minimum bid price requirement ($1.00 per share). It has a 180-day grace period to regain compliance. Failure to do so could result in delisting.
- Liquidity Risk: If the merger does not close by Q2 2025, the company will need to seek alternative capital strategies, which may not be available on acceptable terms, potentially leading to liquidation.
Investor Verification Checklist
- Verify the closing conditions and timeline for the merger with Crescent Biopharma, Inc., and the associated $200 million private placement.
- Monitor the company's stock price to ensure compliance with Nasdaq listing requirements (minimum $1.00 bid price) to avoid delisting.
- Assess the dilution impact on current shareholders, who are expected to retain only ~3.1% ownership post-merger.
- Review the status of the $1.63 million accrued severance liability and the remaining lease obligations ($0.27 million).
- Confirm the company's ability to fund operations through the merger closing given the current cash burn rate and lack of committed funding outside the merger transaction.